Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer.

Standard

Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. / Stoehr, Robert; Wissmann, Christoph; Suzuki, Hiromu; Knuechel, Ruth; Krieg, Rene C; Klopocki, Eva; Dahl, Edgar; Wild, Peter; Blaszyk, Hagen; Sauter, Guido; Simon, Ronald; Schmitt, Ruediger; Zaak, Dirk; Hofstaedter, Ferdinand; Rosenthal, Andre; Baylin, Stephen B; Pilarsky, Christian; Hartmann, Arndt.

In: LAB INVEST, Vol. 84, No. 4, 4, 2004, p. 465-478.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Stoehr, R, Wissmann, C, Suzuki, H, Knuechel, R, Krieg, RC, Klopocki, E, Dahl, E, Wild, P, Blaszyk, H, Sauter, G, Simon, R, Schmitt, R, Zaak, D, Hofstaedter, F, Rosenthal, A, Baylin, SB, Pilarsky, C & Hartmann, A 2004, 'Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer.', LAB INVEST, vol. 84, no. 4, 4, pp. 465-478. <http://www.ncbi.nlm.nih.gov/pubmed/14968126?dopt=Citation>

APA

Stoehr, R., Wissmann, C., Suzuki, H., Knuechel, R., Krieg, R. C., Klopocki, E., Dahl, E., Wild, P., Blaszyk, H., Sauter, G., Simon, R., Schmitt, R., Zaak, D., Hofstaedter, F., Rosenthal, A., Baylin, S. B., Pilarsky, C., & Hartmann, A. (2004). Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. LAB INVEST, 84(4), 465-478. [4]. http://www.ncbi.nlm.nih.gov/pubmed/14968126?dopt=Citation

Vancouver

Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. LAB INVEST. 2004;84(4):465-478. 4.

Bibtex

@article{80fda58b14064ed7a1655bce9229d582,
title = "Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer.",
abstract = "Many molecular alterations are known to occur in urothelial carcinoma of the bladder, but their significance for tumor progression is poorly understood. Deletions of chromosome 8p are frequently found in several tumor types and are often associated with progressive disease. In all, 99 bladder tumors were screened for deletions at 8p using loss of heterozygosity (LOH) and multicolor fluorescence in situ hybridization FISH analyses. Allelic loss on chromosome 8p in at least one marker was found in 25/99 (25%) tumors. There was a significant correlation of 8p deletions with invasive tumor growth and a highly significant association with papillary growth pattern in patients with invasive disease. cDNA array analyses revealed that secreted Frizzled-related protein 1 (sFRP1), an antagonist of Frizzled receptors and Wnt pathway activation on chromosome 8p12-11.1, is frequently downregulated in bladder cancer. To investigate sFRP1 as a candidate for a putative progression-related gene on 8p, urothelial cell lines and primary urothelial carcinomas were screened for sFRP1 expression using quantitative real-time PCR, Northern blot, immunofluorescence and immunohistochemistry (IHC). Of the investigated bladder cancers, 38% showed loss of sFRP1 expression by quantitative RT-PCR. Evaluation of the protein expression by IHC using tissue microarrays containing 776 bladder cancers revealed loss or strong reduction of sFRP1 expression in 66% of cases. SFRP1 loss was associated with higher tumor stage and grade and shorter overall survival. In addition, loss of sFRP1 was an independent indicator of poor survival in patients with papillary but not with muscle invasive bladder cancer. There were neither mutations in the coding region of sFRP1 nor homozygous deletions at 8p12-11.21. However, promoter methylation was detected using methylation-specific PCR in 29% of cases. In conclusion, we could show a close correlation of chromosome 8p deletions and progression of papillary bladder tumors. The sFRP1 gene on chromosome 8p12-11.1 could be a candidate gene for the predicted, progression-related tumor suppressor gene in bladder cancer and could contribute to urothelial carcinogenesis.",
author = "Robert Stoehr and Christoph Wissmann and Hiromu Suzuki and Ruth Knuechel and Krieg, {Rene C} and Eva Klopocki and Edgar Dahl and Peter Wild and Hagen Blaszyk and Guido Sauter and Ronald Simon and Ruediger Schmitt and Dirk Zaak and Ferdinand Hofstaedter and Andre Rosenthal and Baylin, {Stephen B} and Christian Pilarsky and Arndt Hartmann",
year = "2004",
language = "Deutsch",
volume = "84",
pages = "465--478",
journal = "LAB INVEST",
issn = "0023-6837",
publisher = "NATURE PUBLISHING GROUP",
number = "4",

}

RIS

TY - JOUR

T1 - Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer.

AU - Stoehr, Robert

AU - Wissmann, Christoph

AU - Suzuki, Hiromu

AU - Knuechel, Ruth

AU - Krieg, Rene C

AU - Klopocki, Eva

AU - Dahl, Edgar

AU - Wild, Peter

AU - Blaszyk, Hagen

AU - Sauter, Guido

AU - Simon, Ronald

AU - Schmitt, Ruediger

AU - Zaak, Dirk

AU - Hofstaedter, Ferdinand

AU - Rosenthal, Andre

AU - Baylin, Stephen B

AU - Pilarsky, Christian

AU - Hartmann, Arndt

PY - 2004

Y1 - 2004

N2 - Many molecular alterations are known to occur in urothelial carcinoma of the bladder, but their significance for tumor progression is poorly understood. Deletions of chromosome 8p are frequently found in several tumor types and are often associated with progressive disease. In all, 99 bladder tumors were screened for deletions at 8p using loss of heterozygosity (LOH) and multicolor fluorescence in situ hybridization FISH analyses. Allelic loss on chromosome 8p in at least one marker was found in 25/99 (25%) tumors. There was a significant correlation of 8p deletions with invasive tumor growth and a highly significant association with papillary growth pattern in patients with invasive disease. cDNA array analyses revealed that secreted Frizzled-related protein 1 (sFRP1), an antagonist of Frizzled receptors and Wnt pathway activation on chromosome 8p12-11.1, is frequently downregulated in bladder cancer. To investigate sFRP1 as a candidate for a putative progression-related gene on 8p, urothelial cell lines and primary urothelial carcinomas were screened for sFRP1 expression using quantitative real-time PCR, Northern blot, immunofluorescence and immunohistochemistry (IHC). Of the investigated bladder cancers, 38% showed loss of sFRP1 expression by quantitative RT-PCR. Evaluation of the protein expression by IHC using tissue microarrays containing 776 bladder cancers revealed loss or strong reduction of sFRP1 expression in 66% of cases. SFRP1 loss was associated with higher tumor stage and grade and shorter overall survival. In addition, loss of sFRP1 was an independent indicator of poor survival in patients with papillary but not with muscle invasive bladder cancer. There were neither mutations in the coding region of sFRP1 nor homozygous deletions at 8p12-11.21. However, promoter methylation was detected using methylation-specific PCR in 29% of cases. In conclusion, we could show a close correlation of chromosome 8p deletions and progression of papillary bladder tumors. The sFRP1 gene on chromosome 8p12-11.1 could be a candidate gene for the predicted, progression-related tumor suppressor gene in bladder cancer and could contribute to urothelial carcinogenesis.

AB - Many molecular alterations are known to occur in urothelial carcinoma of the bladder, but their significance for tumor progression is poorly understood. Deletions of chromosome 8p are frequently found in several tumor types and are often associated with progressive disease. In all, 99 bladder tumors were screened for deletions at 8p using loss of heterozygosity (LOH) and multicolor fluorescence in situ hybridization FISH analyses. Allelic loss on chromosome 8p in at least one marker was found in 25/99 (25%) tumors. There was a significant correlation of 8p deletions with invasive tumor growth and a highly significant association with papillary growth pattern in patients with invasive disease. cDNA array analyses revealed that secreted Frizzled-related protein 1 (sFRP1), an antagonist of Frizzled receptors and Wnt pathway activation on chromosome 8p12-11.1, is frequently downregulated in bladder cancer. To investigate sFRP1 as a candidate for a putative progression-related gene on 8p, urothelial cell lines and primary urothelial carcinomas were screened for sFRP1 expression using quantitative real-time PCR, Northern blot, immunofluorescence and immunohistochemistry (IHC). Of the investigated bladder cancers, 38% showed loss of sFRP1 expression by quantitative RT-PCR. Evaluation of the protein expression by IHC using tissue microarrays containing 776 bladder cancers revealed loss or strong reduction of sFRP1 expression in 66% of cases. SFRP1 loss was associated with higher tumor stage and grade and shorter overall survival. In addition, loss of sFRP1 was an independent indicator of poor survival in patients with papillary but not with muscle invasive bladder cancer. There were neither mutations in the coding region of sFRP1 nor homozygous deletions at 8p12-11.21. However, promoter methylation was detected using methylation-specific PCR in 29% of cases. In conclusion, we could show a close correlation of chromosome 8p deletions and progression of papillary bladder tumors. The sFRP1 gene on chromosome 8p12-11.1 could be a candidate gene for the predicted, progression-related tumor suppressor gene in bladder cancer and could contribute to urothelial carcinogenesis.

M3 - SCORING: Zeitschriftenaufsatz

VL - 84

SP - 465

EP - 478

JO - LAB INVEST

JF - LAB INVEST

SN - 0023-6837

IS - 4

M1 - 4

ER -